Researchers at NCI Center for Cancer Research have identified extrachromosomal DNA as a major driver of small cell lung cancer, highlighting a novel biomarker and therapeutic target that could be used to eliminate the most aggressive and shapeshifting SCLC cells. The study was published in Cancer Discovery.
People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to an analysis by Johns Hopkins Kimmel Cancer Center investigators.
